Key result
Immunization of mice with recombinant SC602 derivatives expressing IpaC-C3 hybrid proteins demonstrated that specific insertion sites within IpaC can induce serum and local anti-C3 antibodies.
Answers are grounded in this paper and cite their sources.
Supports IpaC-C3 hybrids for preclinical antibody induction; leaves open translation to human vaccine efficacy or safety.
We have investigated the capacity of live attenuated Shigella flexneri strains to act as vectors for the induction of local and systemic antibody responses against heterologous epitopes. The S. flexneri IpaC antigen was selected as a carrier protein into which the C3 neutralizing epitope of the poliovirus VP1 protein was inserted in eight sites distributed along IpaC. The resulting IpaC-C3 hybrid proteins were expressed from recombinant plasmids in the S. flexneri 2a vaccine candidate, SC602. Their production was similar to that of wild-type IpaC. All of the hybrid proteins but one were secreted as efficiently as wild-type IpaC. Immunization of mice with each of the recombinant SC602 derivatives reveals that one construct is able to induce serum and local anti-C3 antibodies, showing that at least one permissive site of insertion within IpaC can be defined. Furthermore, mouse-to-mouse variability in the anti-C3 response indicates that the amount of hybrid proteins produced in the host by SC602 should be improved for optimal use of S. flexneri live attenuated strains as mucosal vectors for foreign epitopes.
No takes yet. Share an insight, caveat, or question.
Bârzu et al. (1998) studied Shigella flexneri vaccine development. SC602 expressing IpaC-C3 hybrid proteins vs. Wild-type SC602 and SC602(pC1) was evaluated on Serum and local anti-C3 IgG and IgA antibody titers. Immunization of mice with recombinant SC602 derivatives expressing IpaC-C3 hybrid proteins demonstrated that specific insertion sites within IpaC can induce serum and local anti-C3 antibodies.
Synapse has enriched 10 related papers. Consider them for comparative context: